Faramarzi Sepideh, Ghafouri-Fard Soudeh
Department of Medical Genetics, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Immunotherapy. 2017 Sep;9(12):1019-1034. doi: 10.2217/imt-2017-0083.
Prostate cancer is a prevalent disorder among men with a heterogeneous etiological background. Several molecular events and signaling perturbations have been found in this disorder. Among genes whose expressions have been altered during the prostate cancer development are cancer-testis antigens (CTAs). This group of antigens has limited expression in the normal adult tissues but aberrant expression in cancers. This property provides them the possibility to be used as cancer biomarkers and immunotherapeutic targets. Several CTAs have been shown to be immunogenic in prostate cancer patients and some of the have entered clinical trials. Based on the preliminary data obtained from these trials, it is expected that CTA-based therapeutic options are beneficial for at least a subset of prostate cancer patients.
前列腺癌是一种在病因背景各异的男性中普遍存在的疾病。在这种疾病中发现了几种分子事件和信号扰动。在前列腺癌发展过程中其表达发生改变的基因中，癌 - 睾丸抗原（CTA）是其中之一。这类抗原在正常成人组织中表达有限，但在癌症中表达异常。这一特性使它们有可能被用作癌症生物标志物和免疫治疗靶点。几种CTA已被证明在前列腺癌患者中具有免疫原性，其中一些已进入临床试验。基于从这些试验中获得的初步数据，预计基于CTA的治疗方案至少对一部分前列腺癌患者有益。
